These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 29576386)
1. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017. Terpos E; Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):321-334. PubMed ID: 29576386 [TBL] [Abstract][Full Text] [Related]
2. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016. Terpos E; Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):329-339. PubMed ID: 28462890 [TBL] [Abstract][Full Text] [Related]
3. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma. Glavey SV; Ghobrial IM Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827 [TBL] [Abstract][Full Text] [Related]
4. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035 [TBL] [Abstract][Full Text] [Related]
5. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018. Terpos E; Ntanasis-Stathopoulos I; Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371 [TBL] [Abstract][Full Text] [Related]
6. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506 [TBL] [Abstract][Full Text] [Related]
7. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221 [TBL] [Abstract][Full Text] [Related]
8. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706 [TBL] [Abstract][Full Text] [Related]
9. Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016. Tandon N; Kumar SK Indian J Hematol Blood Transfus; 2017 Jun; 33(2):153-158. PubMed ID: 28596644 [TBL] [Abstract][Full Text] [Related]
10. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931 [TBL] [Abstract][Full Text] [Related]
11. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities. Guman T; Sykora J Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839 [TBL] [Abstract][Full Text] [Related]
12. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180 [TBL] [Abstract][Full Text] [Related]
13. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation. Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670 [TBL] [Abstract][Full Text] [Related]
15. Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Lahoud OB; Landau H; Nguyen J; Devlin S; Lendvai N; Weltz J; Ayorinde T; Chung DJ; Lesokhin AM; Kewalramani T; Korde N; Mailankody S; Landgren O; Giralt S; Comenzo RL; Hassoun H Leuk Lymphoma; 2022 Sep; 63(9):2126-2135. PubMed ID: 35648041 [TBL] [Abstract][Full Text] [Related]
16. Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy. Rocchi S; Zannetti BA; Marconi G; Lanza F Cells; 2024 May; 13(10):. PubMed ID: 38786075 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Cavo M; San-Miguel J; Usmani SZ; Weisel K; Dimopoulos MA; Avet-Loiseau H; Paiva B; Bahlis NJ; Plesner T; Hungria V; Moreau P; Mateos MV; Perrot A; Iida S; Facon T; Kumar S; van de Donk NWCJ; Sonneveld P; Spencer A; Krevvata M; Heuck C; Wang J; Ukropec J; Kobos R; Sun S; Qi M; Munshi N Blood; 2022 Feb; 139(6):835-844. PubMed ID: 34289038 [TBL] [Abstract][Full Text] [Related]
19. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891 [TBL] [Abstract][Full Text] [Related]
20. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments. Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C Front Oncol; 2020; 10():624661. PubMed ID: 33680948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]